Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 11INDUSTRY 5NETWORK 2OTHER_GOV 1NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 5Multiple Myeloma 3Leukemia 3Burkitt Lymphoma 3Neoplasms 2Myelodysplastic Syndromes 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Solid Tumors 1Solid Tumor 1Rhabdomyosarcoma 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Neoplasms by Site 1Nasopharyngeal Carcinoma 1Melanoma 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Myelomonocytic, Juvenile 1Hodgkin Disease 1Hematopoietic System--Cancer 1Hematologic Neoplasms 1Hematologic Diseases 1Graft vs Host Disease 1Fibrosis Of Extraocular Muscles, Congenital, 3A, with or without Extraocular Involvement 1Disease Progression 1

Interventions

fludarabine phosphate 1fludarabine 1Injections 1Cyclophosphamide 1COVID-19 Vaccines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Hematologic Diseases × Cyclophosphamide × Clear all
NCT05755854 2023-09-22

Allogeneic γ9δ2 T Cells Treatment of Recurrent Hematologic Tumors

Anhui Provincial Hospital

Phase 1 Unknown
10 enrolled

Hematologic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡